TG Therapeutics Overview
- Year Founded
-
1993
- Status
-
Public
- Employees
-
399
- Stock Symbol
-
TGTX
- Investments
-
1
- Share Price
-
$63.34
- (As of Friday Closing)
TG Therapeutics General Information
Description
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
Contact Information
Website
www.tgtherapeutics.comCorporate Office
- 3020 Carrington Mill Boulevard
- Suite 475
- Morrisville, NC 27560-5435
- United States
Corporate Office
- 3020 Carrington Mill Boulevard
- Suite 475
- Morrisville, NC 27560-5435
- United States
TG Therapeutics Stock Performance
As of 20-Nov-2026, TG Therapeutics’s stock price is $63.34. Its current market cap is $9.6B with 151M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $63.34 | $64.85 | $26.76 - $68.03 | $9.6B | 151M | 1.92M | $0.74 |
TG Therapeutics Financials Summary
As of 30-Sep-2026, TG Therapeutics has a trailing 12-month revenue of $898M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 8,740,385 | 4,854,753 | 4,598,294 | 2,466,834 |
| Revenue | 897,763 | 616,287 | 329,004 | 233,662 |
| EBITDA | 196,504 | 134,361 | 49,902 | 26,100 |
| Net Income | 106,058 | 447,179 | 23,383 | 12,672 |
| Total Assets | 1,592,252 | 1,063,253 | 577,690 | 329,587 |
| Total Debt | 754,373 | 253,710 | 253,719 | 110,795 |
TG Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
TG Therapeutics Comparisons
Industry
Financing
Details
TG Therapeutics Competitors (17)
One of TG Therapeutics’s 17 competitors is Pfizer (Vienna), a Corporation company based in Vienna, Austria.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pfizer (Vienna) | Corporation | Vienna, Austria | ||||
| Pfizer Pakistan | Corporation | Karachi, Pakistan | ||||
| Aytu Biopharma | Formerly VC-backed | Denver, CO | ||||
| Gesynta Pharma | Venture Capital-Backed | Stockholm, Sweden | ||||
| Gilead | Formerly VC-backed | Foster City, CA |
TG Therapeutics Patents
TG Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026165590-A1 | Subcutaneous formulations of therapeutic agents | Pending | 03-Feb-2025 | ||
| AU-2025241863-A1 | Subcutaneous formulations of anti-cd20 antibody | Pending | 18-Mar-2024 | ||
| WO-2025199155-A1 | Subcutaneous formulations of anti-cd20 antibody | Pending | 18-Mar-2024 | ||
| AU-2023281714-A1 | Anti-cd20 antibody compositions | Pending | 01-Jun-2022 | ||
| EP-4286010-A1 | Anti-cd20 antibody compositions | Pending | 01-Jun-2022 | C07K16/2887 |
TG Therapeutics Signals
TG Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
TG Therapeutics Acquisitions (1)
TG Therapeutics’s most recent deal was a Merger/Acquisition with Manhattan Pharmaceuticals. The deal was made on 12-Mar-2010.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Manhattan Pharmaceuticals | 12-Mar-2010 | Merger/Acquisition | Pharmaceuticals |
TG Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
34.18 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
TG Therapeutics FAQs
-
When was TG Therapeutics founded?
TG Therapeutics was founded in 1993.
-
Where is TG Therapeutics headquartered?
TG Therapeutics is headquartered in Morrisville, NC.
-
What is the size of TG Therapeutics?
TG Therapeutics has 399 total employees.
-
What industry is TG Therapeutics in?
TG Therapeutics’s primary industry is Pharmaceuticals.
-
Is TG Therapeutics a private or public company?
TG Therapeutics is a Public company.
-
What is TG Therapeutics’s stock symbol?
The ticker symbol for TG Therapeutics is TGTX.
-
What is the current stock price of TG Therapeutics?
As of 20-Nov-2026 the stock price of TG Therapeutics is $63.34.
-
What is the current market cap of TG Therapeutics?
The current market capitalization of TG Therapeutics is $9.6B.
-
What is TG Therapeutics’s current revenue?
The trailing twelve month revenue for TG Therapeutics is $898M.
-
Who are TG Therapeutics’s competitors?
Pfizer (Vienna), Pfizer Pakistan, Aytu Biopharma, Gesynta Pharma, and Gilead are some of the 17 competitors of TG Therapeutics.
-
What is TG Therapeutics’s annual earnings per share (EPS)?
TG Therapeutics’s EPS for 12 months was $0.74.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process